Compare Abeona Therapeutics Inc (ABEO) vs Teladoc Health Inc (TDOC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Teladoc Health Inc — how do they compare? Abeona Therapeutics Inc trades at $6.73 (market cap $373.32M), while Teladoc Health Inc trades at $9.14 (market cap $1.72B). The key difference: Teladoc Health Inc is far larger — about 4.6× Abeona Therapeutics Inc's market cap. Which is the better fit depends on your goals.
| ABEO | TDOC | |
|---|---|---|
Market Cap | $373.32M | $1.72B |
Sector | Health | Health |
52-Week High | $7.23 | $9.52 |
52-Week Low | $4.17 | $4.47 |
Enterprise Value | $228.22M | $2.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Teladoc Health (TDOC) trades at $9.52, up 3.48% today, with technical indicators showing bullish momentum despite overbought RSI readings. The company reported Q1 2026 earnings that missed expectations, but revenue remains stable at $2.53 billion for 2025. Recent news highlights expansion through Walmart's platform and ongoing cost-cutting efforts, though BetterHelp segment weakness persists. Analyst consensus is mixed with 33% buy ratings but a price target below current levels at $7.83.
TDOC's recovery story faces headwinds from persistent net losses and negative cash flow, but low P/S ratio of 0.66 offers valuation appeal. Key risks include competitive pressure and execution challenges, while institutional sentiment remains cautious with no sell ratings. The stock's near-term direction hinges on Q2 earnings results and progress toward profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Teladoc Health Inc
Teladoc Health is a virtual health provider with a telehealth platform delivering 24-hour, on-demand healthcare via mobile devices, the internet, video, and phone. It also offers remote patient monitoring programs for chronic care management. Its platform connects members with a network of physicians and behavioral health professionals. Most of the company's revenue is generated from access fees on a subscription basis (per member, per month). The balance comes from visit fees and equipment rental and sales to hospital systems. Since inception, Teladoc has primarily partnered with employers, health plans, and health systems to offer network access to their members.
Read more on TDOC →
